Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders
Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.
You may also be interested in...
One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.
BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.
US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.